title: Management of myelodysplastic syndromes: 2008 update.
abstract: Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic disorders characterized by low blood counts and a tendency to progress to acute myeloid leukemia. Treatment options have increased over the past 10 years, and many new agents are currently being investigated. In this article, we review the diagnosis of MDS, prognostic systems, and treatment options, including supportive care, erythropoiesis-stimulating agents, antithymocyte globulin, lenalidomide, azacitidine, decitabine, intensive chemotherapy, and hematopoietic cell transplantation.
authors.affiliation: University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. bscott@fhcrc.org
authors.forename: Bart L
authors.initials: BL
authors.lastname: Scott
authors.forename: Eli
authors.initials: E
authors.lastname: Estey
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D002986:Clinical Trials as Topic; D000077209:Decitabine; D018572:Disease-Free Survival; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy*; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D006397:Hematinics; D007155:Immunologic Factors; D007502:Iron Chelating Agents; D016179:Granulocyte Colony-Stimulating Factor; D013792:Thalidomide; D000077209:Decitabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000077269:Lenalidomide; D001374:Azacitidine